



Editorial

Introduction of AIMS Cell and Tissue Engineering

Paul J Kemp *

Editor in Chief of AIMS Cell and Tissue Engineering, School of Biosciences, Cardiff University, UK

* **Correspondence:** Email: Kemp@cardiff.ac.uk; Tel: +44 (0) 29-2087-9347.

Upon talking to academic colleagues around the globe, other than raising grant income, the most common irritation amongst even very high profile scientists, is the time, effort and cost of publishing, especially if the research is ground-breaking, controversial or cross-discipline. Where do you send your work, who will review it, will they be appropriate, how long will it take, how much will it cost and will it be accessible to all? In launching a new Journal, these problems need to be addressed in order for innovative research to receive the recognition it deserves. Enter, *AIMS Cell and Tissue Engineering*.

In welcoming you to an exciting new quarterly on-line journal, *AIMS Cell and Tissue Engineering*, I can, as the new Editor-in-Chief, promise a rapid and objective review process, followed by free and almost instant Open Access for your accepted article. My name is Paul Kemp, and I am Professor of Physiology in the School of Biosciences at Cardiff University in the UK which was, until recently, the academic home of Professor Sir Martin Evans, the joint recipient of the Nobel Prize for Physiology or Medicine in 2007 for the development of stem cell biology and the first transgenic mouse.

One of the most exciting areas emerging in the 21st century at the interfaces between basic science, medicine and biotechnology centres around our ability to engineer biological systems, empowering researchers to design novel approaches for disease diagnosis, modelling and, ultimately, effective and permanent treatment. As new technologies rapidly emerge, their adoption, evolution and utilization for cell or tissue replacement, and drug discovery continues apace.

Launching a Journal which specifically targets such innovations in cell and tissue engineering, and its translational potential is truly a challenge. However, we will strive to make *AIMS Cell and Tissue Engineering* the “go-to” journal for publishing high quality, cutting-edge research in the general field of cell and tissue engineering, but with a focus on cross-disciplinary, state-of-art research in the complementary fields of Matrix Engineering, Translational Stem Cell Science, Tissue Repair & Replacement, Disease Modelling and Drug Discovery.

The success of this approach will be dependent upon your contributions, and we aim to craft each issue of *AIMS Cell and Tissue Engineering* by melding invited reviews from established leaders in the field with a original research publications including:

1. Novel Protocol and Methods Papers
2. Fast-Track, Late-Breaking Translational Communications
3. Fast-Track, Late-Braking Basic Science Communications
4. Original Articles

These could be in the areas of:

- a) Cell Biology
- b) Histology
- c) Cell and tissue culture
- d) Stem Cell Technology
- e) Biomedical Engineering
- f) Hematology
- g) Dermatology
- h) Biomaterials
- i) Transplantation
- j) Construction of engineered tissues and organs

AIMS Cell and Tissue Engineering will take the lead in inviting biotech and pharmaceutical companies to contribute state-of-the art reviews and original articles under the umbrella title of “Biotech News”, in order to facilitate active collaboration in areas of joint interest between industry and academia, thus enhancing the rate of progress towards new treatments and medicines.

Together with our expert Editorial Board, we look forward to receiving your research articles. Each article will be thoroughly peer-reviewed by leaders in the field and our team of Editors will be delighted to enable publication in an efficient and swift manner, free of charge and completely Open Access.

Best wishes for us all at *AIMS Cell and Tissue Engineering*.



AIMS Press

© 2017 Paul J Kemp, licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)